Latanoprost acid

Research use only, not for human use.

Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway.

Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes.

Latanoprost acid (10-20 μM;24 hours) reduces he protein expressions of c-fos and NFATc1. Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK. Latanoprost acid (10 μM, 20 μM) significantly inhibits the mature osteoclast formation. Western Blot Analysis Cell Line:Bone marrow-derived macrophages cells (BMMs) Concentration:10 μM, 20 μM Incubation Time:24 hours Result:Reduced he protein expressions of c-fos and NFATc1.

Latanoprost acid (i.p.; 20 mg/kg; once a day for 7 days) notably prevents LPS-induced bone destruction at a dose of 20mg/kg. Animal Model:8-week-old C57BL/6J mice Dosage:20 mg/kg Administration: Intraperitoneally injected; once a day for 7 days Result:Notably prevented LPS-induced bone destruction at a dose of 20mg/kg.

——

Cell Cycle/DNA Damage

GPR

GPR

——

——

41639-83-2

390.51

C23H34O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (256.08 mM; Ultrasonic )

O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O)CCc1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years